Table 3 The predictors for virological suppression defined as HIV viral load < 400 copies/ml at week 48 of boosted protease inhibitor-based antiretroviral regimens
Proportion of children with viral suppression n(%) | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
Odd Ratios (95%CI) | P-value | Odd Ratios (95%CI) | P-value | ||
ARV regimens | |||||
Single-boosted PI | 54/65(83.1%) | 1 | 1 | ||
Double-boosted PI | 63/79 (79.8%) | 0.80 (0.34-1.88) | 0.611 | 0.82 (0.27-2.42) | 0.712 |
Gender | |||||
Male | 62/69 (89.9%) | 3.22 (1.27-8.20) | 0.014 | 2.85 (1.06-7.66) | 0.018 |
Female | 55/75 (73.3%) | 1 | 1 | ||
Age, years | |||||
< 9.1 | 67/76 (88.2%) | 2.68 (1.12-6.46) | 0.028 | 3.60 (1.25-10.36) | 0.038 |
≥ 9.1 | 50/68 (73.5%) | 1 | 1 | ||
Weight for age Z-score | |||||
< −1.7 | 42/59 (71.2%) | 1 | 1 | ||
≥ − 1.7 | 64/72 (88.9%) | 3.24 (1.28-8.18) | 0.013 | 2.42 (0.85-6.84) | 0.097 |
CD4 at time of switch to second line regimen | |||||
< 100 cell/mm3 | 30/42 (71.4%) | 1 | 1 | ||
≥100 cell/mm3 | 84/99 (84.9%) | 2.24 (0.94-5.33) | 0.068 | 2.12 (0.71-6.36) | 0.178 |
Plasma HIV RNA at time of switch | |||||
< 4 log10 copies/ml | 25/29 (86.2%) | 1.53 (0.48-4.86) | - | - | |
≥ 4 log10 copies/ml | 25/111 (80.4%) | 1 | 0.474 | ||
Mono/dual NRTI exposure | |||||
Yes | 41/50 (82.0%) | 1.08 (0.45-2.62) | 0.867 | ||
No | 76/94 (80.9%) | 1 | |||
Duration on NNRTI-based | |||||
< 2.2 year | 69/84(82.1%) | 1.15 (0.50-2.67) | 0.745 | ||
≤ 2.2 year | 48/60(80.0%) | 1 | |||
NNRTI –based regimen | |||||
NVP-based | 81/96 (84.4%) | 1.80 (0.77-4.23) | 0.178 | 1.24 (0.43-3.55) | 0.691 |
EFV-based | 36/48 (75.0%) | 1 | 1 | ||
Multi-NRTI resistance | 0.809 | - | - | ||
No TAMs | 25/32 (78.1%) | 1 | |||
Low grade multi-NRTI | 35/44 (79.6%) | 1.09 (0.36-3.31) | |||
High grade multi-NRTI | 36/43 (83.7%) | 1.44 (0.45-4.62) | |||
LPV/r in the regimen | |||||
Yes | 60/71 (84.5%) | 1.53 (0.66-3.58) | 0.325 | ||
No | 57/73 (78.1%) | 1 | |||